Sign up to save your podcasts
Or
Share Ocular Therapeutix’ bold vision to redefine retinal disease treatment
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ocular Therapeutix’ bold vision to redefine retinal disease treatment
Pravin Dugel, CEO of Ocular Therapeutix provides insights into existing treatments and future product candidates for retinal diseases, underlining the unique challenges, opportunities and innovations in this evolving landscape.
www.ocutx.com
Pravin U. Dugel, MD Biography
View all episodes
By RBC Capital Markets
5
1212 ratings
Pravin Dugel, CEO of Ocular Therapeutix provides insights into existing treatments and future product candidates for retinal diseases, underlining the unique challenges, opportunities and innovations in this evolving landscape.
www.ocutx.com
Pravin U. Dugel, MD Biography
More shows like Pathfinders in Biopharma
View all
Motley Fool Money
3,218 Listeners
WSJ Your Money Briefing
1,710 Listeners
Exchanges
976 Listeners
Odd Lots
1,869 Listeners
WSJ Tech News Briefing
1,633 Listeners
a16z Podcast
1,084 Listeners
The Long Run with Luke Timmerman
124 Listeners
The Readout Loud
324 Listeners
Wall Street Breakfast
1,030 Listeners
Thoughts on the Market
1,293 Listeners
The Journal.
6,064 Listeners
BioCentury This Week
34 Listeners
RBC's Markets in Motion
40 Listeners
Biotech Hangout
19 Listeners
Industries in Motion
10 Listeners
Powering Sustainable Ideas
1 Listeners
The Markets
77 Listeners
Strategic Alternatives
19 Listeners
The Top Line
15 Listeners
Macro Minutes
3 Listeners